title: Improved efficacy of therapeutic vaccination with viable human umbilical vein endothelial cells against murine melanoma by introduction of OK432 as adjuvant.
abstract: Vaccination with xenogeneic or syngeneic endothelial cells targeting tumor angiogenesis is effective for inhibiting tumor growth. OK432, an effective adjuvant, was mixed with viable human umbilical vein endothelial cells (HUVECs) to prepare a novel HUVECs-OK432 vaccine, which could have an improved therapeutic efficacy. In this study, HUVECs-OK432 was administrated in mice by subcutaneous injection in a therapeutic procedure. The results showed that a stronger HUVEC-specific Abs and cytotoxic T lymphocyte immune response were elicited, which resulted in significant inhibition on the growth of B16F10 melanoma and remarkably prolonged survival of B16F10 melanoma-bearing mice compared with HUVECs. Besides, parallel results were obtained in vitro showing a stronger inhibition of HUVEC proliferation by immune sera of HUVECs-OK432 than that of HUVECs. Moreover, histochemistry and immunohistochemistry analysis showed that HUVECs-OK432 induced large areas of continuous necrosis within tumors and significantly reduced the vessel density, correlating well with the extent of tumor inhibition. Our present results suggest that OK432 could be employed as an effective adjuvant for HUVEC vaccines and therefore should be useful for adjuvant immunotherapy of cancer.
authors: Minigene Pharmacy Laboratory, School of Life Science and Technology, China Pharmaceutical University, 24 Tongjia Xiang, Nanjing, 210009, People's Republic of China. xumaolei1234@163.com
authors: Maolei
authors: M
authors: Xu
authors: Yun
authors: Y
authors: Xing
authors: Ling
authors: L
authors: Zhou
authors: Xue
authors: X
authors: Yang
authors: Wenjun
authors: W
authors: Yao
authors: Wen
authors: W
authors: Xiao
authors: Chiyu
authors: C
authors: Ge
authors: Yanjun
authors: Y
authors: Ma
authors: Jie
authors: J
authors: Yang
authors: Jie
authors: J
authors: Wu
authors: Rongyue
authors: R
authors: Cao
authors: Taiming
authors: T
authors: Li
authors: Jingjing
authors: J
authors: Liu
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D004797:Enzyme-Linked Immunosorbent Assay; D061307:Human Umbilical Vein Endothelial Cells / Q000276:immunology*; D006801:Humans; D008214:Lymphocytes / Q000166:cytology / Q000276:immunology; D008297:Male; D008546:Melanoma, Experimental / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D010844:Picibanil / Q000627:therapeutic use*; D015996:Survival Rate; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014407:Tumor Cells, Cultured; D014611:Vaccination
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D010844:Picibanil